Tower Research Capital (TRC)’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.75K Hold
190
– – ﹤0.01% 4776
2026
Q1
$1.43K Sell
190
-1
-0.5% -$9 ﹤0.01% 4666
2025
Q4
$1.68K Buy
191
+95
+99% +$1.68K ﹤0.01% 4653
2025
Q3
$2.73K Buy
96
+23
+32% +$496 ﹤0.01% 4588
2025
Q2
$981 Sell
73
-1
-1% -$11 ﹤0.01% 4894
2025
Q1
$576 Buy
74
+1
+1% +$9 ﹤0.01% 4868
2024
Q4
$562 Buy
+73
New +$1.67K ﹤0.01% 5236
2024
Q3
– Sell
-62
Closed -$7.35K – 5892
2024
Q2
$7.35K Buy
62
+23
+59% +$3.13K ﹤0.01% 4473
2024
Q1
$7.91K Sell
39
-14
-26% -$2.49K ﹤0.01% 4114
2023
Q4
$8.62K Sell
53
-9
-15% -$1.52K ﹤0.01% 4487
2023
Q3
$6.07K Buy
62
+51
+464% +$9.39K ﹤0.01% 4646
2023
Q2
$2.88K Sell
11
-17
-61% -$5.95K ﹤0.01% 5139
2023
Q1
$10K Buy
28
+6
+27% +$2.27K ﹤0.01% 4377
2022
Q4
$8K Sell
22
-4
-15% -$2K ﹤0.01% 4427
2022
Q3
$12K Buy
+26
New +$15.3K ﹤0.01% 4356
2022
Q2
– Sell
-7
Closed -$5K – 6362
2022
Q1
$5K Buy
+7
New +$3.86K ﹤0.01% 5077
2021
Q4
– Sell
-61
Closed -$60K – 6399
2021
Q3
$60K Buy
+61
New +$39.5K ﹤0.01% 2810
2021
Q2
– Sell
-105
Closed -$83K – 5705
2021
Q1
$83K Buy
105
+95
+950% +$95.6K ﹤0.01% 2731
2020
Q4
$10K Buy
+10
New +$6.95K ﹤0.01% 4316
2020
Q3
– Hold
0
– – – 4997
2020
Q2
– Hold
0
– – – 4891
2020
Q1
– Hold
0
– – – 3581
2018
Q3
– Sell
-7
Closed -$2K – 4073
2018
Q2
$2K Buy
+7
New +$3.03K ﹤0.01% 3345
2018
Q1
– Sell
-28
Closed -$25K – 3627
2017
Q4
$25K Buy
+28
New +$27K ﹤0.01% 1885
2017
Q3
– Sell
-18
Closed -$18K – 4024
2017
Q2
$22K Buy
+18
New +$36.2K ﹤0.01% 1166

Other funds holding MTNB

Tower Research Capital (TRC)'s MTNB Position: Q2 2026 in Review

Tower Research Capital (TRC) held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 190 shares worth $1.75K. The position accounts for ﹤0.01% of the portfolio, ranked #4776.

Tower Research Capital (TRC) first reported a position in MTNB in Q2 2017 and has held it in 22 quarters since. The position peaked at $83K in Q1 2021. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Tower Research Capital (TRC) held 190 shares of Matinas BioPharma worth $1.75K as of Q2 2026.
  • Tower Research Capital (TRC) left its Matinas BioPharma share count unchanged in Q2 2026.
  • Matinas BioPharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4776 holding.
  • Tower Research Capital (TRC) first reported a position in Matinas BioPharma in Q2 2017 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Matinas BioPharma position peaked at $83K in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.